课题基金 / 基金详情

IMAGING SEROTONIN FUNCTIONING IN ASPERGER'S DISORDERS

IMAGING SEROTONIN FUNCTIONING IN ASPERGER'S DISORDERS
亚斯伯格症中血清素功能的成像
批准号:
6670926
负责人:
MARC A LARUELLE
金额:
$20.57万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2008-04-30

项目摘要

项目成果

MARC A LARUELLE的其他基金

相似基金

相关文献

中文摘要
翻译
几条线索的证据暗示,血清素能系统在阿斯伯格症的病理生理。具体来说,选择性5-羟色胺再摄取抑制剂(SSRIs)和5-HT2A拮抗剂的治疗效果、来自外周标志物研究的数据、5-羟色胺合成的脑成像研究以及5-羟色胺药物的药理挑战结果都表明,5-羟色胺传递的缺陷可能导致了这种疾病的症状。然而,目前关于大脑5-羟色胺的具体信息很少
英文摘要
Several lines of evidence implicate the serotonergic system in the pathophysiology of Asperger's disorder. Specifically, the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs) and 5-HT2A antagonists, data from studies of peripheral markers, brain imaging studies of 5-HT synthesis and the results of pharmacological challenges with 5-HT agents converge in suggesting that a deficit in 5-HT transmission might contribute to the symptoms of this illness. However, very little specific information is currently available regarding the brain 5-HT system in patients with Asperger's disorder. Over the last few years, the development of new and highly selective radiotracers has greatly increased the ability to image 5-HT function in the living human brain with Positron Emission Tomography (PET). Combined with progress in scanner resolution and sensitivity, these techniques enable the measurement of parameters of 5-HT function in discrete areas of the living brain. The aim of project II is to quantify the anatomical distribution of two key elements of the 5-HT system that have been implicated in Asperger's disorder: the 5-HT transporter (SERT) and the 5-HT2A receptor. SERT availability will be measured with [11C]DASB and 5-HT2A availability will be measured with [11C]MD L 100907. Both radiotracers are newly developed PET agents with excellent imaging properties. Forty adult subjects with Asperger's disorder and forty controls matched for age, gender, IQ and ethnicity will undergo an MRI scan and two PET scans with [11C]DASB and [11C]MDL 100907, respectively. Subjects will be recruited and evaluated by the Clinical Core of the Center. Following the scans, subjects will be treated with fluoxetine in another study. The hypothesis is that patients with Asperger's disorder will show reduced density of SERT and a compensatory upregulation of 5-HT2A receptors in several areas of the limbic system. Based on results of previous functional brain imaging studies, we anticipate that these changes will be most severe in forebrain cortico-limbic areas. The relationship between regional 5-HT abnormalities and symptom clusters as evaluated by the Clinical Core will be assessed. The results of the imaging studies will also be correlated with the results of a clinical trial with fluoxetine, with the hypothesis that patients who show larger deficits in 5-HT function will be the most likely to benefit from fluoxetine treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mesolimbic DA D1/D2 Receptors and Response to Cocaine
SUBCORTICAL DA FUNCTION IN SCHIZOPHRENIA
IMAGING SEROTONIN FUNCTIONING IN ASPERGER'S DISORDERS
PET IN ESCTASY USERS
海外基金